Home
LIPO
LIPO News

Latest Lipella Pharmaceuticals Inc. (LIPO) News on April 1, 2025

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

GlobeNewswire

a day ago

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Spartan Capital Securities, LLC Announces Key February Transactions

GlobeNewswire

25 days ago

Spartan Capital Securities, LLC Announces Key February Transactions

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement

GlobeNewswire

a month ago

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement

MT Newswires

2 months ago

Top Midday Gainers

MT Newswires

2 months ago

Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes

Benzinga

2 months ago

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes

MT Newswires

2 months ago

Top Premarket Gainers

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

GlobeNewswire

2 months ago

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

MT Newswires

2 months ago

Top Midday Gainers

MT Newswires

2 months ago

Top Premarket Gainers

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

GlobeNewswire

2 months ago

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

GlobeNewswire

3 months ago

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

GlobeNewswire

4 months ago

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

GlobeNewswire

4 months ago

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)

Simply Wall St.

4 months ago

Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

GlobeNewswire

5 months ago

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

MT Newswires

5 months ago

Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

GlobeNewswire

5 months ago

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

GlobeNewswire

5 months ago

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

GlobeNewswire

6 months ago

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

6 months ago

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

GlobeNewswire

6 months ago

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

GlobeNewswire

6 months ago

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

GlobeNewswire

7 months ago

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

GlobeNewswire

7 months ago

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

GlobeNewswire

7 months ago

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)

Simply Wall St.

8 months ago

Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)

Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial

Clinical Trials Arena

8 months ago

Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

GlobeNewswire

8 months ago

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

MT Newswires

8 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires

8 months ago

Sector Update: Health Care

MT Newswires

8 months ago

Top Midday Gainers

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

GlobeNewswire

8 months ago

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

GlobeNewswire

10 months ago

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire

10 months ago

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

GlobeNewswire

10 months ago

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)

Simply Wall St.

a year ago

Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

GlobeNewswire

a year ago

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

GlobeNewswire

a year ago

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

GlobeNewswire

a year ago

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

GlobeNewswire

a year ago

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

GlobeNewswire

a year ago

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)

Simply Wall St.

a year ago

Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

GlobeNewswire

a year ago

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

GlobeNewswire

a year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

Rent the Runway, Inc. (RENT) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a year ago

Rent the Runway, Inc. (RENT) Upgraded to Buy: What Does It Mean for the Stock?

Greenwave Technology Solutions Generates More than $9 Million Revenue in Q4 2023

PR Newswire

a year ago

Greenwave Technology Solutions Generates More than $9 Million Revenue in Q4 2023

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

Business Wire

a year ago

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

The Arena Group Announces Workforce Reductions in Strategic Move to Transform the Business Model

Business Wire

a year ago

The Arena Group Announces Workforce Reductions in Strategic Move to Transform the Business Model

Altisource Asset Management Corporation Repurchases Preferred Shares in Global Settlement With Luxor Capital

Business Wire

a year ago

Altisource Asset Management Corporation Repurchases Preferred Shares in Global Settlement With Luxor Capital

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?

Simply Wall St.

a year ago

When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?

Genius Group Announces Pricing of $8.25 Million Public Offering

GlobeNewswire

a year ago

Genius Group Announces Pricing of $8.25 Million Public Offering

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

Business Wire

a year ago

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

GlobeNewswire

a year ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

GlobeNewswire

a year ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

Business Wire

a year ago

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

GlobeNewswire

a year ago

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

PR Newswire

a year ago

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Banzai Announces Premier AI Webinar Host, Demio AI, to Elevate On-Demand Events

GlobeNewswire

a year ago

Banzai Announces Premier AI Webinar Host, Demio AI, to Elevate On-Demand Events

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

GlobeNewswire

a year ago

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Faraday Future Continues Actions to Protect Stockholders Against Potential Illegal Trading Activities

Business Wire

a year ago

Faraday Future Continues Actions to Protect Stockholders Against Potential Illegal Trading Activities

Ondas Holdings Inc. (NASDAQ:ONDS) Shares Could Be 32% Above Their Intrinsic Value Estimate

Simply Wall St.

a year ago

Ondas Holdings Inc. (NASDAQ:ONDS) Shares Could Be 32% Above Their Intrinsic Value Estimate

Fuel Tech Awarded Air Pollution Control and Chemical Technologies Orders Totaling $2.5 Million

Business Wire

a year ago

Fuel Tech Awarded Air Pollution Control and Chemical Technologies Orders Totaling $2.5 Million

The Arena Group Announces Termination Of CEO Ross Levinsohn, Appoints Manoj Bhargava As Interim CEO

Business Wire

a year ago

The Arena Group Announces Termination Of CEO Ross Levinsohn, Appoints Manoj Bhargava As Interim CEO

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire

a year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Build Better Journalist Relationships with These Three Tips from ACCESSWIRE

ACCESSWIRE

a year ago

Build Better Journalist Relationships with These Three Tips from ACCESSWIRE

Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023

PR Newswire

a year ago

Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023

Carver Bancorp, Inc. Interim CEO Craig C. MacKay Comments on the Bank's Recent Performance

PR Newswire

a year ago

Carver Bancorp, Inc. Interim CEO Craig C. MacKay Comments on the Bank's Recent Performance

Vroom Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Vroom Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Polished.com Announces Results for Third Quarter of 2023 and Amendment of Credit Agreement

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

GlobeNewswire

a year ago

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

GlobeNewswire

a year ago

Interactive Strength Inc. d/b/a FORME Reports Third Quarter 2023 Results

Business Wire

a year ago

Polished.com Postpones Reporting of Third Quarter 2023 Financial Results

Associated Press Finance

a year ago

Scynexis: Q3 Earnings Snapshot

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

PR Newswire

a year ago

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

Business Wire

a year ago

Polished.com Announces Date for Third Quarter 2023 Earnings Release

Share on Social Networks: